Chronic Hand Eczema: Clinical Insights, Patient Experience, and Emerging Therapeutics - Episode 7
The Future of Chronic Hand Eczema Treatment
Published on:
An expert discusses how new treatments for chronic hand eczema (CHE) are emerging, particularly topical delgocitinib cream, a pan-Janus kinase (JAK) inhibitor that shows promise for treating multiple etiologies of the condition without the limitations of traditional topical steroids.
Video content above is prompted by the following:
Future Directions of CHE Treatment
Key Themes:
- Emerging therapies: Topical delgocitinib cream, a pan-JAK inhibitor, shows promise specifically for CHE.
- Other investigational options: Topical ruxolitinib, dupilumab, and tralokinumab have shown efficacy in certain CHE populations.
- Clinical approach: Avoiding treatment delays while pursuing diagnostic workup, with consideration for targeted therapies across multiple etiologies.
Notable Insights:
Dr Chovatiya emphasized that "having a cream that can help patients across etiologies and not delay their actual treatment represents a huge potential win for us in dermatology," suggesting a paradigm shift in CHE management.
